Novel CD22 CAR-T Works After CD19 Product Failed Novel CD22 CAR-T Works After CD19 Product Failed
A novel CAR T-cell therapy directed against CD22 worked in children with acute lymphoblastic leukemia who had previously progressed after receiving CD19-directed CAR T-cell therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Liver Cancer Doubled in High-Income Countries Liver Cancer Doubled in High-Income Countries
Rates of liver cancer have doubled since the 1990s in high-income countries and are largely due to infection with hepatitis B and C, as well as nonalcoholic fatty liver disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Reducing Unplanned Acute Care for Patients With Cancer Reducing Unplanned Acute Care for Patients With Cancer
Early use of palliative care and identification of patients at risk are strategies that may reduce acute care in patients with cancer.Journal of Oncology Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Exercise Rx Boosts Marker of Heart Health in Cancer Patients
(MedPage Today) -- Intervention doubled peak oxygen consumption (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 17, 2018 Category: Hematology Source Type: news

Endoscopic Surveillance Detects Early Gastric Cancer
(MedPage Today) -- But low yield shows need for better tests to identify patients at risk of progression (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 16, 2018 Category: Hematology Source Type: news

Q & A with Dr. Otis Brawley, chief medical officer of the American Cancer Society
Atlanta Business Chronicle on June 13 spoke to Dr. Otis Brawley, and professor of the department of hematology and medical oncology at Emory University School of Medicine. Brawley spoke about his concerns with the American health-care system, proton beam therapy and working for Grady Memorial Hospital. You wrote a book in 2011, "How We Do Harm: A Doctor Breaks Ranks About Being Sick in America." What made you want to write that? I had been reflecting on cancer care and there were a bunch of things… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 15, 2018 Category: Biotechnology Authors: Ellie Hensley Source Type: news

Q & A with Dr. Otis Brawley, chief medical officer of the American Cancer Society
Atlanta Business Chronicle on June 13 spoke to Dr. Otis Brawley, and professor of the department of hematology and medical oncology at Emory University School of Medicine. Brawley spoke about his concerns with the American health-care system, proton beam therapy and working for Grady Memorial Hospital. You wrote a book in 2011, "How We Do Harm: A Doctor Breaks Ranks About Being Sick in America." What made you want to write that? I had been reflecting on cancer care and there were a bunch of things… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 15, 2018 Category: Pharmaceuticals Authors: Ellie Hensley Source Type: news

DNA Analysis in Early Breast Ca Reveals Markers of Recurrence
(MedPage Today) -- And PIK3CA mutations tied to letrozole benefit over tamoxifen (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 15, 2018 Category: Hematology Source Type: news

Targeted Tx Yields'Striking' Response Rate in Follicular Lymphoma
(MedPage Today) -- Responses durable even in fourth-line setting (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 15, 2018 Category: Hematology Source Type: news

MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
Initiation of registration study for ME-401 in patients with relapsed or refractory follicular lymphoma expected before year-end SAN DIEGO, June 15, 2018 -- (Healthcare Sales & Marketing Network) -- MEI Pharma, Inc. (NASDAQ: MEIP) a pharmaceutical comp... Biopharmaceuticals, Oncology MEI Pharma, follicular lymphoma, chronic lymphocytic lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 15, 2018 Category: Pharmaceuticals Source Type: news

AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
83 percent (n=100) of 121 patients who achieved undetectable minimal residual disease (uMRD) at the end of combination therapy with VenR (n=194), maintained uMRD and were progression-free at 13.8 months of follow-up[1] uMRD response rates were consisten... Biopharmaceuticals, Oncology AbbVie, MURANO trial, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 15, 2018 Category: Pharmaceuticals Source Type: news

Higher Vitamin D Levels Tied to Lower Colorectal Cancer Risk Higher Vitamin D Levels Tied to Lower Colorectal Cancer Risk
Higher vitamin D levels in the blood may protect against colorectal cancer, especially in women, but optimal concentrations may be higher than levels currently recommended for bone health.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 15, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from the final analysis of the CLL11 study evaluating Gazyva®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: World Pharma News)
Source: World Pharma News - June 15, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche today announced data from the final analysis of the CLL11 study evaluating Gazyva ®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: Roche Investor Update)
Source: Roche Investor Update - June 15, 2018 Category: Pharmaceuticals Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche today announced data from the final analysis of the CLL11 study evaluating Gazyva ®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: Roche Media News)
Source: Roche Media News - June 15, 2018 Category: Pharmaceuticals Source Type: news

Time Is Up for PD-L1 Testing Standardization in Lung Cancer Time Is Up for PD-L1 Testing Standardization in Lung Cancer
Rapid efforts are needed to determine analytical concordance between PD-L1 assays.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 15, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

JAK inhibitors associated with aggressive lymphoma
(American Society of Hematology) Austrian researchers have discovered that a small number of patients taking targeted drugs known as Janus kinase (JAK) inhibitors to treat myelofibrosis may develop aggressive lymphomas. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 15, 2018 Category: Cancer & Oncology Source Type: news

Chemo Adverse Events More Frequent in Female Colon Cancer Patients Chemo Adverse Events More Frequent in Female Colon Cancer Patients
Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Race May Be Factor in Completion of Neoadjuvant Breast CA Chemo Race May Be Factor in Completion of Neoadjuvant Breast CA Chemo
White women with breast cancer are more likely to complete their neoadjuvant chemotherapy regimen than women of color, a U.S. study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Trastuzumab Biosimilar on Par With Reference Product in Early Breast Cancer Trastuzumab Biosimilar on Par With Reference Product in Early Breast Cancer
Safety, efficacy and clinical outcomes were similar for Amgen's trastuzumab biosimilar ABP 980 and the trastuzumab reference product in women with HER2-positive early breast cancer in the LILAC study, researchers reported June 4 at the 2018 ASCO Annual Meeting.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

When Online Information Is the'Third Party in the Exam Room'When Online Information Is the'Third Party in the Exam Room '
There is too much information for doctors to'know it all ’ anymore. Drs West, Pal, and Gilligan discuss the changing doctor-patient relationship, including when patients become the educators.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Omega-3 Fatty Acids Reduce Pain From AIs at BMI of 30 or More Omega-3 Fatty Acids Reduce Pain From AIs at BMI of 30 or More
Omega-3 fatty acids significantly reduced pain among very overweight women who take aromatase inhibitors (AIs) for breast cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Transplant in Myeloma Ups Survival, but Is Underutilized Transplant in Myeloma Ups Survival, but Is Underutilized
Stem cell transplant improves survival in patients with multiple myeloma, but why is it still underutilized?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Hype, Fear of Failure Driving Immunotherapy'Hail Mary' Treatments Hype, Fear of Failure Driving Immunotherapy'Hail Mary' Treatments
John Marshall speaks with Leonard Saltz and Tanios Bekaii-Saab about the destructive trend of trying experimental drugs before having the data, and the new'right to try'law.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Talking to Cancer Patients About Genetic Testing
(MedPage Today) -- Managing expectations, next steps when the results come back (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 13, 2018 Category: Hematology Source Type: news

Tips on Advising, Treating Cancer Patients After Genetic Testing
(MedPage Today) -- Managing expectations, next steps when the results come back (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 13, 2018 Category: Hematology Source Type: news

A Better Regimen for Head and Neck Cancer?
(MedPage Today) -- Study backs combo of chemotherapy, cetuximab, and radiotherapy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 13, 2018 Category: Hematology Source Type: news

Helping Cancer Patients to Understand New'Right-to-Try' Law Helping Cancer Patients to Understand New'Right-to-Try' Law
The new measure should have been called the'right-to-ask'law, as the decision about whether to provide experimental drugs still rests with pharma companies, says one expert.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

At ASCO, Noninferiority Trials Dominate, Prove'Less Can Be More'At ASCO, Noninferiority Trials Dominate, Prove'Less Can Be More '
Three of the biggest trials at the 2018 annual meeting of the American Society of Clinical Oncology involved reducing therapy while maintaining efficacy.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Managing Cancer Pain in the Era of an Opioid Crisis Managing Cancer Pain in the Era of an Opioid Crisis
An expert panel discussed management and strategies for caring for patients and avoiding misuse of opioids, and also touched on growing concerns of limited access.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

NSCLC: Nivolumab Extends 5-Year Survival in Heavily Pretreated Patients
(MedPage Today) -- In phase I study, no evidence of progression or need for subsequent therapy in 12 of 16 patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 13, 2018 Category: Hematology Source Type: news

Dendritic Vaccine for Glioblastoma: Hope Hyped, Say Some Dendritic Vaccine for Glioblastoma: Hope Hyped, Say Some
Survival for patients with newly diagnosed glioblastoma may be given a boost if initial results of dendritic vaccines using patients'own cells hold up. But experts are skeptical.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

TAILORx Provides'Clear Answer' for ER+ Breast Cancer TAILORx Provides'Clear Answer' for ER+ Breast Cancer
Lead investigator Joseph Sparano discusses the pivotal TAILORx trial presented at ASCO 2018. It's a'great day for patients,'says Kathy Miller.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 13, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Morning Break: Keytruda for Cervical Ca; Head Transplant'Imminent'; LSD Depression Fix
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 13, 2018 Category: Hematology Source Type: news

Uveal Melanoma: Better Survival With Liver-Directed Therapy Uveal Melanoma: Better Survival With Liver-Directed Therapy
Treatment for liver metastases in uveal cancer has changed over 50 years. At ASCO, one study charted the survival benefits seen with newer localized therapies; the other showed benefits of radioembolization.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Lower Survival With Checkpoint Inhibitors in Bladder Cancer Lower Survival With Checkpoint Inhibitors in Bladder Cancer
Agencies in both the United States and Europe have warned about a decreased survival in patients treated with checkpoint inhibitors compared with those receiving chemotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

$200K Saved With First-Line Docetaxel for Prostate Cancer $200K Saved With First-Line Docetaxel for Prostate Cancer
For the first time, there is a cost-effectiveness study on two systemic drugs used in the treatment of newly diagnosed metastatic prostate cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Expanded Criteria for Active Surveillance in Prostate Cancer Expanded Criteria for Active Surveillance in Prostate Cancer
Could active surveillance inclusion criteria be safely expanded? If so, which patients should be included?Translational Andrology and Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

HIV Suppression Seems to Cut Cancer Risk in Veterans' Study (CME/CE)
(MedPage Today) -- Greatest risk reduction among AIDS-defining cancers (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 12, 2018 Category: Hematology Source Type: news

Emojis Help Cancer Patients Report Symptoms, QoL Emojis Help Cancer Patients Report Symptoms, QoL
Wearable technologies and emoji mood scales could be the future of patient-reported outcome assessment in cancer patients, suggested a US study presented at the world's largest cancer meeting.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 11, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Cancer Burden on the Rise in Much of the World Cancer Burden on the Rise in Much of the World
The global cancer burden is rising, but some of that increase is in potentially preventable cancers that lifestyle interventions could reduce.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 11, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

10 Questions to Challenge Your Medical News Savvy
(MedPage Today) -- Weekly Quiz: June 1-6 (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 9, 2018 Category: Hematology Source Type: news

Medical News Today: Serum iron test: High, low, and normal ranges
A serum iron test can tell doctors whether a person has low, healthy, or high iron levels. Normal levels vary between individuals, but having a result outside the standard ranges may indicate a health problem. Learn the possible causes of an abnormal serum iron test result, and how to treat the underlying conditions. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 9, 2018 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Next-Gen Sequencing for Lung Cancer: Do It Early, for All Next-Gen Sequencing for Lung Cancer: Do It Early, for All
Dr Mark Kris talks about the advantages of next-gen sequencing, from obtaining valuable bioinformatics to detecting rare abnormalities.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 9, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

EGFR Inhibitor Shows Signal in Triple-Negative Inflammatory Breast Ca
(MedPage Today) -- Small single-arm study reports high pCR rate, finds potential markers of response (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 8, 2018 Category: Hematology Source Type: news

Fosaprepitant Safe and Effective for Chemo-induced Nausea in Kids Fosaprepitant Safe and Effective for Chemo-induced Nausea in Kids
Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

In Missouri, J & J Faces Biggest Trial Yet Alleging Talc Caused Cancer In Missouri, J & J Faces Biggest Trial Yet Alleging Talc Caused Cancer
A lawsuit by 22 ovarian cancer patients against Johnson& Johnson went to trial on Wednesday in Missouri state court, marking the largest case the company has faced over allegations its talc-based products contain cancer-causing asbestos.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Upfront MRI Could Rule Out Prostate Ca in Most, Reduce Biopsy Need
(MedPage Today) -- Less-costly biparametric MRI can spare men from TRUS biopsy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 8, 2018 Category: Hematology Source Type: news

Neoadjuvant CRT May Improve Survival in Pancreatic Cancer Neoadjuvant CRT May Improve Survival in Pancreatic Cancer
Results are preliminary, but patients who received neoadjuvant chemoradiation had better outcomes than did those who had immediate surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Neurocognitive Function in Survivors of Childhood Cancer Neurocognitive Function in Survivors of Childhood Cancer
Chronic conditions as a result of cancer therapy can impact neurocognitive function of childhood cancer survivors.Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news